Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-1 Registration statement (foreign)
- 3.1 Exhibit 3.1
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 10.16 Exhibit 10.16
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 99.1 Exhibit 99.1
Associated filings
- 18 May 20 424B4 Prospectus supplement with pricing info
- 15 May 20 EFFECT Notice of effectiveness
- 14 May 20 F-1/A Registration statement (foreign) (amended)
- 11 May 20 F-1/A Registration statement (foreign) (amended)
- 27 Apr 20 F-1/A Registration statement (foreign) (amended)
-
24 Apr 20 F-1 Registration statement (foreign)
ADCT similar filings
Filing view
External links
Exhibit 99.1
Consent of Chief Financial Officer Nominee
ADC Therapeutics SA is filing a Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering of its common shares. In connection therewith, I hereby consent to being named as a nominee to the position of Chief Financial Officer of ADC Therapeutics SA in the Registration Statement, as may be amended from time to time. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
By: | /s/ Jennifer Creel | |
Name: | Jennifer Creel | |
Date: | April 24, 2020 |